PMID- 27683606
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160929
LR  - 20201001
IS  - 2045-8932 (Print)
IS  - 2045-8940 (Electronic)
IS  - 2045-8932 (Linking)
VI  - 6
IP  - 3
DP  - 2016 Sep
TI  - A systematic review and meta-analysis of trials using statins in pulmonary 
      arterial hypertension.
PG  - 295-301
LID - 10.1086/687304 [doi]
AB  - Statins improve pulmonary vascular remodeling and right ventricular hypertrophy 
      in animal models of pulmonary arterial hypertension (PAH). However, clinical 
      trials assessing the efficacy of statins in patients with PAH have reported mixed 
      results. In this systematic review and meta-analysis, we assess the efficacy of 
      statins in patients with PAH. We included randomized controlled clinical trials 
      (RCTs) that evaluated the efficacy of statins in patients with PAH. Primary 
      outcomes were mortality and change in 6-minute walk distance (6MWD). Data are 
      presented as odds ratio (OR) and weighted mean difference (WMD), with 95% 
      confidence intervals (CIs), for binary and continuous variables, respectively. We 
      included 4 RCTs of high quality. The mean age of participants was 42 +/- 13 years, 
      and 70% were women. The statins used were simvastatin at 40-80 mg in two trials, 
      atorvastatin 10 mg in one trial, and rosuvastatin 10 mg in the other. In the 
      pooled-data analysis, there was no statistically significant improvement in 
      mortality (OR: 0.75 [95% CI: 0.32-1.74]), 6MWD (WMD: -9.27 [95% CI: -27.73 to 
      9.20]), or cardiac index (WMD: 0.11 [95% CI: -0.04 to 0.27]) with statin therapy 
      when compared to placebo. There was no difference in adverse events leading to 
      withdrawal of therapy between statin and placebo groups. These data suggest that 
      statins are not beneficial in the treatment of PAH. There is a need for large, 
      well-conducted clinical trials assessing the effects of statins in patients with 
      PAH. Future trials should include homogeneous patient populations and should be 
      long-term, event-driven trials with combined morbidity and mortality end points.
FAU - Anand, Vidhu
AU  - Anand V
AD  - Cardiovascular Division, Department of Medicine, University of Minnesota, 
      Minneapolis, Minnesota, USA.
FAU - Garg, Sushil
AU  - Garg S
AD  - Cardiovascular Division, Department of Medicine, University of Minnesota, 
      Minneapolis, Minnesota, USA.
FAU - Duval, Sue
AU  - Duval S
AD  - Cardiovascular Division, Department of Medicine, University of Minnesota, 
      Minneapolis, Minnesota, USA.
FAU - Thenappan, Thenappan
AU  - Thenappan T
AD  - Cardiovascular Division, Department of Medicine, University of Minnesota, 
      Minneapolis, Minnesota, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pulm Circ
JT  - Pulmonary circulation
JID - 101557243
PMC - PMC5019082
OTO - NOTNLM
OT  - hemodynamics
OT  - pulmonary embolism
OT  - right ventricle
OT  - vascular remodeling
EDAT- 2016/09/30 06:00
MHDA- 2016/09/30 06:01
PMCR- 2016/09/01
CRDT- 2016/09/30 06:00
PHST- 2016/09/30 06:00 [entrez]
PHST- 2016/09/30 06:00 [pubmed]
PHST- 2016/09/30 06:01 [medline]
PHST- 2016/09/01 00:00 [pmc-release]
AID - PC2013327 [pii]
AID - 10.1086/687304 [doi]
PST - ppublish
SO  - Pulm Circ. 2016 Sep;6(3):295-301. doi: 10.1086/687304.